A qualitative study of the adoption of buprenorphine for opioid addiction treatment

Journal of Substance Abuse Treatment

Volumn 46, Issue 3, 2014, Pages 390-401

  Green, Carla A ^a   McCarty, Dennis ^b   Mertens, Jennifer ^c   Lynch, Frances L ^a   Hilde, Anadam ^d   Firemark, Alison ^a   Weisner, Constance M ^c   Pating, David ^e   Anderson, Bradley M ^e  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

Buprenorphine; Diffusion of technology; Implementation research; Medication adoption; Opioid addiction; Qualitative research

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ADMINISTRATIVE PERSONNEL; ARTICLE; CASE MANAGEMENT; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG SAFETY; FOLLOW UP; HARM REDUCTION; HUMAN; LEADERSHIP; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENTAL HEALTH; METHADONE TREATMENT; OPIATE ADDICTION; OPTIMISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PESSIMISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; REHABILITATION CARE; RESIDENTIAL CARE; SEMI STRUCTURED INTERVIEW; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME;

BUPRENORPHINE; DIFFUSION OF TECHNOLOGY; IMPLEMENTATION RESEARCH; MEDICATION ADOPTION; OPIOID ADDICTION; QUALITATIVE RESEARCH;

ANALGESICS, OPIOID; BUPRENORPHINE; EVALUATION STUDIES AS TOPIC; HUMANS; OPIOID-RELATED DISORDERS;

EID: 84892482605     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.09.002     Document Type: Article

References (26)

1. Abraham A.J., Ducharme L.J., Roman P.M. Counselor attitudes toward pharmacotherapies for alcohol dependence. Journal of Studies on Alcohol and Drugs 2009, 70(4):628-635.
2. Barry C.L., Huskamp H.A. Moving beyond parity-Mental health and addiction care under the ACA. New England Journal of Medicine 2011, 365(11):973-975.
3. Buck J.A. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs (Project Hope) 2011, 30(8):1402-1410.
4. Damschroder L.J., Aron D.C., Keith R.E., Kirsh S.R., Alexander J.A., Lowery J.C. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implementation Science 2009, 4:50.
5. Damschroder L.J., Hagedorn H.J. A guiding framework and approach for implementation research in substance use disorders treatment. Psychology of Addictive Behaviors 2011, 25(2):194-205.
6. Ducharme L.J., Knudsen H.K., Roman P.M., Johnson J.A. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32(4):321-329.
7. Friese, S. (2011). User's Manual for ATLAS.ti 6.0 Berlin: ATLAS.ti Scientific Software Development GmbH. Retrieved from . http://www.atlasti.com/uploads/media/atlasti_v6_manual.pdf.
8. Horgan C.M., Reif S., Hodgkin D., Garnick D.W., Merrick E.L. Availability of addiction medications in private health plans 2007, Journal of Substance Abuse Treatment.
9. Knudsen, H. K., Abraham, A. J., & Roman, P. M. (2011). Adoption and implementation of medications in addiction treatment programs. J Addict Med, 5(1), 21-27. [doi]. doi:10.1097/ADM.0b013e3181d41ddb.
10. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007). The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 87(2-3), 164-174. doi:S0376-8716(06)00305-X [pii]; [doi]. doi:10.1016/j.drugalcdep.2006.08.013.
11. Knudsen H.K., Roman P.M., Ducharme L.J., Johnson J.A. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues 2005, 35:559-574.
12. Lynch, F., McCarty, D., Mertens, J., Perrin, N., Green, C., Parthasarathy, S. et al. (2013). (under review). Costs of care for persons with opioid dependence in two integrated health systems. Addiction Science and Clinical Practice.
13. Mark, T. L., Kassed, C. A., Vandivort-Warren, R., Levit, K. R., & Kranzler, H. R. (2009). Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug and Alcohol Dependence, 99(1-3), 345-349. doi:S0376-8716(08)00305-0 [pii]; [doi]. doi:10.1016/j.drugalcdep.2008.07.018.
14. Mark, T. L., Levit, K. R., Vandivort-Warren, R., Buck, J. A., & Coffey, R. M. (2011). Changes In US spending on Mental Health And Substance Abuse Treatment, 1986-2005, and implications for policy. Health Affairs (Project Hope), 30(2), 284-292. doi:30/2/284 [pii]; [doi]. doi:10.1377/hlthaff.2010.0765.
15. Reif, S., Thomas, C. P., & Wallack, S. S. (2007). Factors determining how early adopter physicians use buprenorphine in treatment. J Addict Med, 1(4), 205-212. [doi];01271255-200712000-00006 [pii]. doi:10.1097/ADM.0b013e31814c3fa8.
16. Rieckmann, T., Daley, M., Fuller, B. E., Thomas, C. P., & McCarty, D. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment, 32(2), 207-215. doi:S0740-5472(06)00307-2 [pii]; [doi]. doi:10.1016/j.jsat.2006.09.002.
17. Rogers E.M. Diffusion of innovations 2003, Free Press, New York. 5th ed.
18. Savage, S. A., Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2012). Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages. Journal of Substance Abuse Treatment, 42(1), 16-24. doi:S0740-5472(11)00118-8 [pii]; [doi]. doi:10.1016/j.jsat.2011.06.009.
19. Substance Abuse and Mental Health Services Administration. (2012a). CSAT Buprenorphine Information Center. Retrieved from . http://buprenorphine.samhsa.gov/data.html.
20. Substance Abuse and Mental Health Services Administration. (2012b). National Survey of Substance Abuse.
21. Thomas C.P., McCarty D. Adoption of drug abuse treatment technology in specialty and primary care settings. New treatments for addiction: Behavioral, ethical, legal and social questions 2004, 140-172. The National Academies Press, Washington, DC. H.J. Harwood, T.G. Myers (Eds.).
22. Thomas C.P., Reif S., Haq S., Wallack S.S., Hoyt A., Ritter G.A. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services 2008, 59(8):909-916.
23. Thomas C.P., Wallack S.S., Lee S., McCarty D., Swift R. Research to practice. Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 2003, 24(1):1-11.
24. Thomas, S. E., Miller, P. M., Randall, P. K., & Book, S. W. (2008). Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. Journal of Substance Abuse Treatment, 35(3), 260-268. doi:S0740-5472(07)00348-0 [pii]; [doi]. doi:10.1016/j.jsat.2007.11.001.
25. Wallack, S. S., Thomas, C. P., Martin, T. C., Chilingerian, J., & Reif, S. (2010). Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication. Journal of Behavioral Health Services & Research, 37(1), 64-78. [doi]. doi:10.1007/s11414-008-9132-4.
26. Walley A.Y., Alperen J.K., Cheng D.M., Botticelli M., Castro-Donlan C., Samet J.H., et al. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 2008, 23(9):1393-1398.